June 29, 2026 · Phase 2 readout
TVRD Phase 2 readout: a positive outcome, +27.3%
On June 29, 2026, TTI-101 — Tvardi Therapeutics, Inc. (Hepatocellular Carcinoma) reached its Phase 2 readout. The result was a positive outcome, and the stock moved +27.3% in the window around the event. It had already run -55.6% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$1.50
1d before
$1.91
Event day
$1.90
1d after
$2.02
5d after
Our prediction vs. the result
CatalystAlert called this one neutral (+0.6% expected); the stock actually moved +27.3%. Model confidence at the time: 40%.
See the full scored track recordPre-catalyst setup
-55.6%
30-day run-up
13659%
30-day volatility
13.8×
volume spike